Advancements in Classical Hodgkin's Lymphoma Treatment

This chapter explores recent progress in treating classical Hodgkin's lymphoma, emphasizing the impact of checkpoint inhibitors and insights into the disease's biology. It discusses the timing of checkpoint blockade, outcomes from autologous stem cell transplantation, and promising improvements in patient survival rates along with manageable toxicities.